global
vaccin
market
divers
face
plethora
novel
develop
genet
modif
gm
techniqu
facilit
design
smarter
vaccin
mani
major
infecti
diseas
human
like
aid
malaria
also
human
neoplast
disord
still
vaccin
avail
may
specul
novel
gm
technolog
significantli
contribut
develop
promis
number
studi
conduct
gm
vaccin
gm
vaccin
technolog
contribut
gm
technolog
newli
introduc
vaccin
market
disappointingli
limit
studi
field
vectorbas
gm
vaccin
explor
data
current
avail
actual
appli
newli
develop
vector
retriev
variou
sourc
synthesis
analys
order
provid
overview
use
vectorbas
technolog
field
gm
vaccin
develop
still
two
vectorbas
vaccin
human
vaccin
market
ampl
activ
field
patent
preclin
research
differ
stage
clinic
research
result
studi
reveal
vectorbas
vaccin
compris
signific
part
gm
vaccin
pipelin
studi
highlight
poxvirus
adenovirus
among
promin
vector
gm
vaccin
develop
approv
first
vector
human
vaccin
base
flaviviru
vector
vaccin
vector
technolog
especi
base
poxvirus
adenovirus
hold
great
promis
futur
vaccin
develop
ever
sinc
discoveri
edward
jenner
two
centuri
ago
vaccinia
viru
could
use
protect
peopl
variola
vaccin
utmost
import
fight
infecti
diseas
cost
effect
tool
prevent
infecti
diseas
date
sever
type
vaccin
avail
includ
liveattenu
inactiv
subunit
split
toxoid
conjug
dna
recombin
vector
vaccin
convent
vaccin
like
liveattenu
inactiv
wildtyp
success
protect
vaccine
variou
infecti
diseas
year
avail
infecti
diseas
afford
convent
vaccin
product
method
predominantli
use
virus
bacteria
product
produc
classic
product
method
labour
intens
expens
time
consum
desir
antigen
produc
way
furthermor
highli
virul
pathogen
produc
expens
special
safeti
condit
attenu
agent
may
tendenc
revert
pathogen
form
usual
use
fulli
compet
individu
overcom
challeng
tradit
vaccin
product
develop
use
novel
gener
vaccin
like
base
gm
technolog
consid
frequent
advent
novel
technolog
may
also
expect
creat
opportun
develop
vaccin
target
new
indic
andor
applic
field
sinc
mani
major
indic
unsatisfactori
vaccin
avail
like
aid
malaria
tuberculosi
exploit
novel
technolog
like
use
vectorbas
vaccin
candid
vectorbas
product
protect
antigen
may
eventu
allow
us
fill
gap
unmet
medic
need
date
sever
vaccin
human
base
gm
technolog
licens
review
see
eg
lot
candid
pipelin
interest
approach
vaccin
develop
base
gm
technolog
use
vector
carri
select
gene
encod
antigen
induc
protect
immun
either
use
vaccin
proper
product
antigen
incorpor
vaccin
present
paper
deal
vector
actual
use
vaccin
product
immunogen
vector
classifi
three
differ
categori
viral
bacteri
plasmid
vector
either
fulli
replic
caus
abort
infect
still
allow
express
desir
immunogen
administ
either
parenter
via
mucos
membran
major
advantag
vectorbas
gm
technolog
immunogen
interest
de
novo
synthes
thu
allow
induct
antibodi
helper
cell
mediat
immun
also
induct
protect
cytotox
cell
respons
mimick
natur
immun
respons
immunogen
balanc
immun
respons
open
pathway
previous
inaccess
tradit
vaccin
technolog
use
nonliv
immunogen
especi
induct
ctl
respons
may
particular
interest
vaccin
certain
viru
infect
cancer
previou
studi
provid
addit
insight
regard
strength
weak
opportun
threat
technolog
present
studi
potenti
vectorbas
vaccin
evalu
data
obtain
literatur
grant
patent
differ
stage
clinic
trial
synthesis
analys
light
data
current
regist
vaccin
provid
overview
potenti
current
use
newli
gener
vector
field
vaccin
develop
data
suggest
vectorbas
vaccin
may
offer
costeffect
altern
product
safe
vaccin
diseas
less
perfect
vaccin
exist
today
thu
cater
huge
unmet
medic
need
method
appli
studi
split
four
differ
stage
evalu
literatur
patent
clinic
trial
regist
gm
nongm
vaccin
stage
individu
examin
detail
complet
data
set
compil
stage
decid
upon
order
provid
complet
overview
genet
modifi
gm
vectorbas
vaccin
pipelin
market
map
earli
research
stage
emerg
vector
literatur
search
perform
avail
candid
vector
vaccin
studi
data
collect
variou
type
gm
vector
properti
mention
research
public
review
search
conduct
use
combin
embas
medlin
webofsci
pubm
cochran
googl
scholar
medic
subject
head
mesh
boolean
oper
utilis
order
develop
basi
syntax
search
restrict
publicationstransl
english
syntax
search
result
analys
independ
biomed
inform
specialist
erasmu
medic
centr
medic
librari
addit
inform
search
term
differ
search
engin
found
support
inform
total
hit
obtain
duplic
remov
result
public
restrict
analysi
includ
articl
describ
vaccin
vaccin
technolog
articl
describ
novel
vaccin
technolog
public
restrict
publish
period
total
set
contain
review
articl
gm
vaccin
order
retriev
paper
vectorbas
gm
vaccin
candid
addit
search
perform
pubm
includ
relev
search
term
vaccin
vector
gm
review
retriev
ad
search
term
review
previous
mention
term
search
review
paper
date
period
collect
new
result
ad
previou
tabl
total
public
specif
topic
vectorbas
vaccin
select
pool
analys
detail
clinic
studi
review
evalu
shown
tabl
result
literatur
studi
found
tabl
patent
multipl
technolog
classif
base
claim
sinc
classifi
technolog
class
patent
relat
gm
vaccin
collect
databas
patent
data
concern
gm
vaccin
retriev
espacenet
provid
access
million
patent
document
worldwid
search
term
use
medicin
prepar
contain
antigen
antibodi
medicin
prepar
contain
genet
materi
insert
cell
live
bodi
treat
genet
diseas
gene
therapi
mutat
genet
engin
dna
rna
concern
genet
engin
vector
eg
plasmid
isol
prepar
purif
use
host
therefor
combin
search
word
vaccin
boolean
oper
genet
modif
respect
result
dedupl
base
prioriti
number
syntax
search
result
analys
patent
specialist
netherland
enterpris
agenc
rvo
government
institut
depart
econom
affair
total
number
uniqu
patent
found
origin
databas
creat
includ
class
subclass
patent
inform
patent
databas
condens
cooper
patent
classif
cpc
code
previou
search
repeat
combin
previou
search
cpc
code
vector
search
term
vaccin
total
uniqu
cpc
code
use
result
vectorbas
vaccin
patent
document
cpc
code
describ
classif
technic
area
variou
level
definit
cpc
code
use
retriev
espacenet
comprehens
tabl
creat
includ
cpc
code
definit
number
patent
contain
specif
code
search
term
found
tabl
result
illustr
fig
complet
overview
cpc
code
descript
found
support
inform
note
clinic
trial
data
phase
gather
world
health
organis
intern
clinic
trial
registri
platform
current
list
studi
countri
data
retriev
may
search
term
appli
found
tabl
result
dedupl
base
trial
id
number
total
uniqu
clinic
trial
use
creat
origin
databas
provid
detail
outlook
use
viral
vector
gm
vaccin
trial
clinic
trial
databas
analys
vector
specif
way
progress
vectorbas
vaccin
share
gm
vaccin
examin
well
spread
specif
vector
preval
specif
indic
data
entri
vector
trial
sort
indic
frequenc
preval
indic
select
form
new
data
subset
subset
analys
specif
type
vector
use
per
indic
comparison
made
indic
complet
dataset
gm
vaccin
result
shown
tabl
data
concern
regist
vaccin
obtain
government
databas
follow
region
usa
eu
brazil
india
china
southafrica
australia
japan
tabl
bric
countri
select
four
five
bric
countri
includ
russia
omit
due
gener
inaccess
russian
regist
rapidli
grow
economi
potenti
industri
current
total
number
regist
human
vaccin
market
dedupl
regist
vaccin
remain
relat
gm
vaccin
boolean
search
term
use
classifi
vaccin
genet
modif
engin
dnarna
recombin
vector
chimer
vlpviruslik
virosom
order
analys
avail
vectorbas
vaccin
market
analysi
perform
databas
vaccin
classifi
vectorbas
order
provid
overview
preval
vector
patent
andor
regist
clinic
trial
two
data
analys
perform
initi
comprehens
patent
databas
creat
describ
analys
data
specif
vector
type
data
combin
data
vector
type
clinic
trial
databas
relev
patent
entri
select
databas
base
presenc
cpc
code
relat
vector
patent
applic
sub
databas
creat
includ
differ
vector
vector
combin
extract
uniqu
patent
mani
vector
appear
time
top
tabl
list
clinic
studi
review
evalu
altenburg
et
al
et
al
arroyo
et
al
nieto
salvetti
babu
appaiahgari
vrati
ondondo
banchereau
steinman
pandey
et
al
et
al
pari
et
al
et
al
ploquin
et
al
chinomb
et
al
rimmelzwaan
sutter
choi
chang
robertson
cottingham
et
al
rollier
et
al
croyl
et
al
saxena
et
al
dick
et
al
smith
tatsi
ertl
ewer
et
al
tripp
tompkin
et
al
ulmer
et
al
hessel
et
al
ura
et
al
kreijtz
et
al
verheust
et
al
lundstrom
weaver
barri
mooney
tompkin
william
et
al
myhr
et
al
youngjoo
et
al
clinic
trial
analysi
similar
procedur
appli
instead
search
cpc
code
data
technolog
class
vaccin
extract
previous
gener
clinic
trial
databas
search
variabl
express
system
relev
data
vector
extract
result
vector
phase
trial
vector
phase
trial
vector
phase
trial
result
analys
shown
fig
order
visualis
progress
gm
vaccin
year
timelin
creat
use
data
avail
databas
patent
clinic
trial
regist
preval
per
indic
per
year
indic
select
base
presenc
databas
six
indic
select
present
patent
clinic
trial
albeit
absent
regist
result
timelin
vaccin
presenc
per
year
indic
span
data
regist
vaccin
india
omit
analysi
inform
date
applic
given
indian
regist
patent
clinic
trial
databas
compris
gm
vaccin
regist
databas
use
entireti
gm
nongm
vaccin
visualis
shown
fig
tabl
provid
inform
frequent
use
vector
mention
literatur
total
viral
bacteri
plasmid
dna
vector
present
tabl
cover
essenti
vector
type
vaccin
product
deliveri
tabl
show
data
sever
upcom
vector
research
eg
new
subtyp
poxvirus
adenovirus
novel
bacteri
vector
furthermor
tabl
compris
indic
mention
vector
advantag
challeng
viral
vector
part
cover
gener
viral
vector
speci
sever
import
main
viral
famili
follow
relev
speci
point
viral
vector
research
detail
bacteri
vector
poxvirus
adenovirus
frequent
mention
literatur
moreov
detail
applic
two
viral
famili
sever
speci
subspeci
vector
vaccin
develop
common
demonstr
tabl
analysi
preval
specif
vector
patent
clinic
trial
present
fig
total
vectorbas
vaccin
patent
evalu
patent
databas
studi
provid
overview
vectorbas
gm
vaccin
pipelin
market
indic
poxvirus
adenovirus
among
promin
vector
gm
vaccin
develop
find
show
vectorbas
vaccin
compris
signific
part
gm
vaccin
pipelin
realis
data
complet
four
differ
stage
research
conduct
analys
detail
stage
cover
literatur
patent
clinic
trial
regist
market
vectorbas
gm
vaccin
gener
idea
evolut
vaccin
gone
year
start
project
becam
clear
gm
vaccin
unambigu
definit
dna
engin
express
system
genet
genet
engin
indic
genet
modifi
live
product
system
liveattenu
modifi
specif
target
recombin
protein
recombin
technolog
class
rna
vector
virosom
type
organ
vlp
total
number
vaccin
dedupl
gm
vaccin
vectorbas
gm
vaccin
continu
next
page
retrovirus
long
term
gene
express
gener
replicationcompet
viru
infect
divid
cell
lentiviru
long
term
gene
express
infect
nondivid
divid
cell
high
immunogen
gener
replicationcompet
viru
potenti
tumorigenesi
bacteria
lactic
acid
bacteria
lactococcu
streptococcu
pediococcu
leuconostoc
lactobacillu
autoimmun
diseas
natur
present
host
much
safer
tradit
attenu
vaccin
children
immunocompromis
peopl
histori
food
industri
recognis
safe
probiot
health
promot
properti
capac
surviv
gastrointestin
tract
mucos
administr
could
reduc
tradit
side
effect
limit
knowledg
avail
use
vector
vaccin
compar
viral
vector
listeria
cancer
induc
cell
respons
natur
present
host
preexist
immun
lead
stronger
immun
respons
much
safer
tradit
attenu
vaccin
children
immunocompromis
peopl
induc
robust
tcell
immun
respons
invad
varieti
cell
includ
antigen
present
cell
resid
cytoplasm
limit
knowledg
avail
use
vector
vaccin
compar
viral
vector
continu
next
page
salmonella
salmonellosi
anim
typhoid
fever
hiv
infect
natur
present
host
preexist
immun
lead
stronger
immun
respons
much
safer
tradit
attenu
vaccin
children
immunocompromis
peopl
induc
robust
tcell
immun
respons
induc
humor
cellular
immun
respons
induc
mucos
system
immun
abl
carri
larg
dna
insert
preexist
immun
could
still
limit
factor
limit
knowledg
avail
use
vector
vaccin
variou
search
term
often
found
literatur
defin
gm
vaccin
nevertheless
term
use
inconsist
manner
definit
gm
vaccin
narrow
delin
search
term
found
cpc
code
literatur
literatur
wide
acknowledg
compar
bacteri
dna
vector
viral
vector
research
detail
tabl
poxvirus
adenovirus
referenc
often
lot
detail
provid
use
famili
viral
vector
nevertheless
preexist
immun
still
major
obstacl
sever
viral
vector
tabl
special
concern
use
adenoviru
vector
although
sever
strategi
circumv
problem
develop
interestingli
mani
data
suggest
seem
le
problem
mva
base
vaccin
candid
comparison
viral
vector
dna
bacteri
vector
show
potenti
respect
requir
research
furthermor
sever
limit
overcom
primari
limit
bacteri
vector
lack
immunogen
compar
viral
vector
addit
virus
rel
easier
work
sinc
less
complex
genom
bacteria
although
sever
type
bacteria
mention
literatur
eg
escherichia
coli
vibrio
cholera
mycobacteria
shigella
spp
mention
tabl
due
lack
suffici
inform
advantag
disadvantag
result
patent
search
show
promin
cpc
code
patent
databas
vectorbas
vaccin
cover
gener
inform
vector
cpc
code
compris
specif
vector
gener
indic
vectorbas
vaccin
larg
varieti
differ
vector
type
patent
vaccin
develop
fig
accord
patent
databas
mastadenoviru
orthopoxviru
vacciniavariola
promin
vector
human
adenovirus
part
mastadenoviru
genu
turn
larg
genu
adenovirida
famili
notabl
orthopoxviru
vacciniavariola
well
poxvirida
appear
patent
result
speci
vaccinia
viru
variola
viru
part
genu
orthopoxviru
belong
famili
poxvirida
explan
behind
seemingli
doubl
occurr
cpc
code
speci
famili
present
espacenet
one
cpc
code
vaccinia
variola
combin
rather
separ
code
speci
clinic
trial
vectorbas
vaccin
play
quit
import
part
gm
vaccin
trial
whole
gm
vaccin
trial
use
vectorbas
candid
vaccin
especi
current
undef
indic
cancer
hiv
tb
malaria
tabl
although
activ
clinic
trial
malaria
base
fowlpox
vector
provid
clinic
trial
databas
clinicaltrialgov
literatur
show
fowlpox
vector
examin
combin
differ
vaccin
regimen
intervent
strategi
diseas
repres
larg
unmet
medic
need
still
caus
million
death
everi
year
limit
cure
avail
new
method
might
provid
addit
valu
vaccin
research
develop
hope
breakthrough
premis
confirm
fig
cancer
hiv
malaria
show
larg
presenc
patent
clinic
trial
databas
hib
hepat
meningococcu
show
littl
develop
patent
clinic
trial
stage
recent
year
impli
lower
need
new
vaccin
technolog
indic
current
vaccin
base
convent
method
appar
suffici
satisfactori
tabl
also
show
littl
vectorbas
vaccin
trial
present
less
treatabl
diseas
hpv
induc
neoplasia
hepat
b
influenza
appar
less
medic
need
vectorbas
vaccin
indic
vaccin
candid
avail
base
gmbase
nongmbas
techniqu
signific
amount
activ
nonvectorbas
gm
trial
three
indic
demonstr
varieti
gm
techniqu
appli
vaccin
develop
influenza
hepat
b
vaccin
product
use
recombin
dna
technolog
alreadi
common
practic
therefor
focu
research
optimis
technolog
use
rather
invest
new
vectorbas
technolog
research
increas
mva
vector
usag
compar
use
vaccinia
viru
indic
mva
start
replac
regular
vaccinia
viru
vectorbas
vaccin
develop
vaccinia
trial
stagnat
mva
trial
increas
rapidli
fig
reason
replac
predominantli
relat
safeti
efficaci
mva
caus
abort
infect
induc
abund
express
target
immunogen
lead
impress
protect
immun
respons
promin
use
adenovirus
viral
vector
probabl
due
consider
knowledg
viru
famili
eas
manipul
viru
use
vectorbas
vaccin
broad
tissu
tropism
associ
viru
consensu
poxvirus
adenovirus
import
vectorbas
gm
vaccin
research
also
strengthen
data
shown
fig
indic
high
preval
vector
patent
clinic
trial
patent
first
two
phase
clinic
trial
orthopoxvirus
vaccinia
viru
mention
combin
variola
viru
adenovirus
well
repres
though
patent
adenovirus
mention
directli
part
mastadenoviru
genu
analys
data
set
import
keep
mind
data
base
use
snapshot
phase
research
develop
pipelin
patent
made
public
month
submiss
patent
retract
month
period
disappear
espacenet
clinic
trial
show
activ
ongo
trial
henc
databas
start
discontinu
termin
trial
remov
databas
consequ
make
direct
correl
databas
unjustifi
therefor
analys
conduct
studi
directli
databas
databas
seen
individu
snapshot
even
though
numer
vector
studi
differ
phase
preclin
clinic
research
presenc
major
phase
indic
evolut
vectorbas
vaccin
begun
larg
amount
vector
type
patent
reach
phase
clinic
trial
show
lot
promis
new
techniqu
might
lead
new
gener
safer
effici
costeffect
vaccin
compar
data
present
literatur
studi
conduct
initi
seem
lot
new
vector
patent
littl
publish
inform
avail
could
indic
vector
patent
beforehand
necessarili
order
start
new
studi
case
method
techniqu
develop
make
suitabl
vaccin
product
without
patent
anyon
could
start
develop
vector
without
legal
consequ
lead
compani
compet
sell
vaccin
lowest
price
possibl
revenu
vaccin
sale
eventu
lead
return
invest
past
futur
research
develop
would
incent
develop
new
gener
vaccin
therefor
use
patent
search
consid
valid
valuabl
approach
gather
part
dataset
conclus
data
suggest
although
current
two
licens
vectorbas
human
vaccin
market
field
still
earli
day
vectorbas
vaccin
may
offer
costeffect
altern
product
safe
effect
vaccin
diseas
less
perfect
vaccin
exist
today
promis
vector
vaccin
develop
moment
appear
poxviru
adenoviru
vector
may
conclud
abund
use
develop
vaccin
diseas
like
hivaid
malaria
tuberculosi
differ
form
neoplast
diseas
may
expect
current
effort
spent
develop
vectorbas
vaccin
may
lead
promis
vaccin
candid
indic
therefor
hold
promis
current
futur
unmet
medic
need
therefor
recent
erad
smallpox
use
jenner
vaccinia
viru
first
vaccin
virus
may
basi
construct
vector
may
help
us
control
major
scourg
mankind
author
declar
conflict
interest
